Fig. 2
Ex vivo biodistribution of [125I]I-OX265-F(ab′)2-Bapi or [124I]I-OX2676-F(ab′)2-Bapi in WT rats. a Concentration (SUV) of [125I]I-OX265-F(ab′)2-Bapi or [124I]I-OX2676-F(ab′)2-Bapi in WT rat brain regions 4 h and 70 h post-administration. b Bispecific fusion protein distribution in brain capillaries and parenchyma 4 h post-administration. c Whole blood elimination curves over 3 days post-administration. Curve fit based on a two-phase decay non-linear regression model. d, e Brain-to-blood ratio (d) and percent in plasma (e) 4 h and 70 h post-administration. f, g Peripheral ex vivo biodistribution (SUV) of [125I]I-OX265-F(ab′)2-Bapi or [124I]I-OX2676-F(ab′)2-Bapi in WT rats 4 h (f) and 70 h (g) post-administration. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001